Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio
Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.
AMPH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AMPH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 61th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 93% on a DCF basis. The most interesting components of our discounted cash flow analysis for Amphastar Pharmaceuticals Inc ended up being:
The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMPH, try CHE, ANTM, FMS, DVA, and ANIP.
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Dan Dischner – Vice President of Human Resources and Corporate Communications Bill Peters – Chief Financial Officer Tony Marrs – Senior Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Tim...
RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (800) 708-4540, five minutes before the conference. The passcode for the conference call is 49844225.The call can also be accessed on the Investors page on the Company’s website www.amphastar.com.Amphastar is a specialty pharmaceutical company that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high techn...